ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
Arcaion / Pixabay

ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency

In early December 2020, mRNA medicines company Arcturus Therapeutics Holdings Inc. ("Arcturus") announced that the company begun dosing participants within its Phase 1b clinical trial. Within the trial, researchers will…

Continue Reading ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
Doctors in Japan Transplant Stem Cells in Six-Day Old Newborn to Treat Urea Cycle Disorder
source: pixabay.com

Doctors in Japan Transplant Stem Cells in Six-Day Old Newborn to Treat Urea Cycle Disorder

  In an article in Medical Xpress, Japanese doctors have performed a “first” by transplanting liver cells (made with embryonic stem cells) into a newborn. The six-day-old infant was diagnosed with…

Continue Reading Doctors in Japan Transplant Stem Cells in Six-Day Old Newborn to Treat Urea Cycle Disorder
Man With Urea Cycle Disorder is the First Person in Canada to be Treated With Intravenous Gene Therapy
NeuPaddy / Pixabay

Man With Urea Cycle Disorder is the First Person in Canada to be Treated With Intravenous Gene Therapy

According to a story from ctvnews.ca, a recent treatment with gene therapy appears to have changed the life of thirty year old Josh McQuillin, who has a urea cycle disorder,…

Continue Reading Man With Urea Cycle Disorder is the First Person in Canada to be Treated With Intravenous Gene Therapy
New Updates From Translate Bio in Drug Development for Cystic Fibrosis and OTC Deficiency
geralt / Pixabay

New Updates From Translate Bio in Drug Development for Cystic Fibrosis and OTC Deficiency

According to a story from globenewswire.com, the messenger RNA therapeutics company Translate Bio recently released the latest updates in regards to two of its leading product candidates for the treatment…

Continue Reading New Updates From Translate Bio in Drug Development for Cystic Fibrosis and OTC Deficiency
CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency
Source: Pixabay

CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency

Another successful partnership in the rare disease community has come to fruition, reports The Pharma Letter. Just this past week, CureVac and Arcturus Therapeutics will become a powerhouse together with…

Continue Reading CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency